Targets › CLEC12A
4 programs from 4 companies in 4 trials: 4 Phase 1; Oncology, Hematology; next expected readout Apr 2028.
Myeloid inhibitory C-type lectin receptor that acts as a negative regulator of myeloid cell activation. Myeloid cell inhibition is required to limit pro-inflammatory pathways and protect against excessive inflammation (By similarity). (UniProt, Q5QGZ9)
Open in Phaseline: the race on CLEC12A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | ADCLEC.syn1 CAR T cells CAR-T cell therapy targeting CLEC12A | CLEC12A | Phase 1 | Acute Myeloid Leukemia | Apr 2028 |
| ARCE Therapeutics | ARD103 anti-CLL-1 CAR-T cell therapy | CLEC12A | Phase 1 | Acute Myeloid Leukemia, in Relapse | Oct 2028 |
| Celyad Oncology | CYAD-02 CAR-T cell therapy targeting CLEC12A | CLEC12A | Phase 1 | Acute Myeloid Leukemia | Feb 2035 |
| Baylor College of Medicine | CLL-1.CAR T cells CAR-T cells targeting CLL-1 antigen | CLEC12A | Phase 1 | Acute Myeloid Leukemia | Jul 2038 |
Acute Myeloid Leukemia (3) Acute Myeloid Leukemia, in Relapse (1)
mixed (2), other (2)
Celyad Oncology (1) ARCE Therapeutics (1) Memorial Sloan Kettering Cancer Center (1) Baylor College of Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.